Get the Stockscreener App
2.35
2.89%
-0.07
Minerva Neurosciences Inc stock is traded at $2.35, with a volume of 85,597.
It is down -2.89% in the last 24 hours and down -32.57% over the past month.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
See More
Previous Close:
$2.42
Open:
$2.42
24h Volume:
85,597
Relative Volume:
0.62
Market Cap:
$112.21M
Revenue:
Net Income/Loss:
$-293.42M
P/E Ratio:
-0.0806
EPS:
-29.1639
Net Cash Flow:
$-14.87M
1W Performance:
-26.10%
1M Performance:
-32.57%
6M Performance:
-62.64%
1Y Performance:
-7.13%
1-Day Range:
$2.30
$2.47
1-Week Range:
$2.28
$3.23
52-Week Range:
$2.28
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Name
Minerva Neurosciences Inc
Sector
Industry
Phone
617-600-7373
Address
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
2.35 | 112.21M | 0 | -293.42M | -14.87M | -29.16 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-26 | Upgrade | Jefferies | Hold → Buy |
| Apr-15-26 | Initiated | Citizens | Mkt Outperform |
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Initiated | BTIG Research | Buy |
| Oct-02-19 | Reiterated | Chardan Capital Markets | Buy |
| Sep-25-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-31-19 | Initiated | H.C. Wainwright | Buy |
| Sep-01-17 | Initiated | Citigroup | Buy |
| Mar-06-17 | Resumed | Jefferies | Buy |
| May-12-16 | Resumed | Jefferies | Buy |
View All
Minerva Neurosciences Inc Stock (NERV) Latest News
Anthony Aliquo Net Worth (2026) - GuruFocus
Minerva Neurosciences Inc. Stock Grades | NERV - Barron's
Minerva Neurosciences Inc Share PriceNERV, RNS News, Articles, Quotes, & Charts (NASDAQ:NERV) - Proactive financial news
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to S&P Global BMI Index - marketscreener.com
Minerva Neurosciences at Cantor conference: roluperidone reset By Investing.com - Investing.com Nigeria
Minerva Neurosciences at Cantor conference: roluperidone reset By Investing.com - Investing.com Canada
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageRevenue Breakdown Analysis - siam.in
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageEPS Consistency Score - dars.gov.et
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageEarnings Seasonality - dars.gov.et
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageGuidance Accuracy Score - https://www.dars.gov.et/
Minerva Neurosciences Inc. (NERV) Q2 2026 Earnings: Wider-Than-Expected EPS Loss Highlights Capital-Intensive Pre-Commercial StageAnalyst Earnings Estimate - dars.gov.et
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - Investing News Network
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - kommunikasjon.ntb.no
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - Yahoo Finance
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - The Manila Times
Minerva (NERV): Loses 0.62% to Close at $4.81 in Latest Trading; Level Watch: the $4.57 to $5.05 Range Remains in Focus for the Current SessionBearish Pattern Stocks - careplusvn.com
Minerva Neurosciences Inc (NASDAQ: NERV) Share Price, NERV Stock News, NERV Share Price & Updates - Kalkine
Balyasny Asset Management L.P. Expands Stake in Minerva Neurosciences Inc (NERV) - GuruFocus
Minerva Neurosciences (NASDAQ: NERV) COO holds 20,872 shares, 750K and 680K options - Stock Titan
NERV Upgraded by Jefferies -- Price Target Raised to $10.00 - GuruFocus
Minerva Neurosciences (NASDAQ:NERV) Downgraded to Strong Sell Rating by Zacks Research - MarketBeat
Minerva Neurosciences, Inc (NASDAQ:NERV) Given Consensus Recommendation of "Reduce" by Brokerages - marketbeat.com
Balyasny Asset Management (NERV) discloses 9.99% Minerva Neurosciences ownership via shares and warrants - Stock Titan
Jefferies Upgrades Minerva Neurosciences(NERV.US) to Buy Rating, Raises Target Price to $10 - Moomoo
Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway By Investing.com - Investing.com Canada
Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway By Investing.com - Investing.com India
Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway By Investing.com - Investing.com UK
Jefferies Maintains Minerva Neurosciences(NERV.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Farallon group discloses 9.7% Minerva Neurosciences (NERV) holding via shares and warrants - Stock Titan
Minerva Neurosciences (NERV) Advances to $3.99, Holding Support as Resistance at $4.19 LoomsHot Stock Picks - vinanet.vn
Minerva Neurosciences (NERV) Advances to $3.99, Holding Support as Resistance at $4.19 LoomsNHNL Ratio - careplusvn.com
Minerva Neurosciences (NERV) Plunges 9% to $3.92: Critical Support Level in FocusTotal Put Call - siam.in
Minerva Neurosciences Elevates Aliquo to Accounting Leadership - TipRanks
Minerva Neurosciences (NERV) elevates Anthony Aliquo to chief accounting officer role - Stock Titan
HC Wainwright Has Bearish Estimate for NERV Q3 Earnings - MarketBeat
H.C. Wainwright Maintains Minerva Neurosciences(NERV.US) With Hold Rating, Maintains Target Price $7 - Moomoo
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME) - The Globe and Mail
Minerva Neurosciences (NASDAQ:NERV) Upgraded at Wall Street Zen - MarketBeat
Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com - Investing.com Nigeria
Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com - Investing.com South Africa
Minerva Neurosciences Q2 adjusted EPS beats estimates on warrant gain - scanx.trade
Minerva Neurosciences Provides Second Quarter 2026 Financial Results And Business Updates - TradingView
Minerva Neurosciences, Inc. Q2 2026: Net income $17.47M, EPS $(0.14) — 10-Q Summary - TradingView
Minerva Neurosciences (NASDAQ: NERV) logs $107.9M loss but holds $75.4M cash - Stock Titan
Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com - Investing.com Canada
Minerva Neurosciences posts Q2 2026 results: GAAP net income $17.5M; cash & equivalents $75.4M - TradingView
Minerva Neurosciences: Q2 Earnings Snapshot - marketscreener.com
Minerva Neurosciences: Q2 Earnings Snapshot - Barchart.com
Minerva Neurosciences reports $17.5 million Q2 net income as Phase 3 trial continues - Quiver Quantitative
Minerva Neurosciences Inc Stock (NERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Minerva Neurosciences Inc Stock (NERV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Federated Hermes Kaufmann Smal | 10% Owner |
Mar 31 '26 |
Proposed Sale |
8.00 |
19,838 |
158,704 |
0 |
| Federated Hermes Kaufmann Fund | 10% Owner |
Mar 31 '26 |
Proposed Sale |
8.00 |
31,808 |
254,464 |
0 |
| Federated Hermes Kaufmann Fund | 10% Owner |
Mar 10 '26 |
Proposed Sale |
8.00 |
12,456 |
99,648 |
0 |
| Federated Hermes Kaufmann Smal | 10% Owner |
Mar 10 '26 |
Proposed Sale |
8.00 |
264,615 |
2,116,920 |
0 |
| Federated Hermes Kaufmann Fund | 10% Owner |
Mar 10 '26 |
Proposed Sale |
8.00 |
424,278 |
3,394,224 |
0 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):